Cellebrite DI Ltd. Ordinary Shares Q2 2026 Earnings Recap

Cellebrite's shares fell 27% after management acknowledged a significant deceleration in deal closings, primarily due to delayed large transactions and weaker-than-expected ARR uplift from their Insights solution, prompting a cut to full-year ARR and revenue guidance.

Key Takeaways

• The anticipated Q2 acceleration in Annual Recurring Revenue (ARR) and revenue did not materialize, largely due to delays in closing several large U.S. federal and European government contracts.
• Additional administrative and procurement hurdles tied to Cellebrite’s foreign entity status impacted timing on major deals.
• The Insights digital forensic product, while adopted by nearly 65% of the installed base, delivered lower ARR uplift than expected, especially in the U.S. state and local government segment.
• Management cited increased complexity in cloud and AI-related deals, involving longer procurement cycles and more stakeholders.
• Reflecting these challenges and delayed product launches, Cellebrite revised downward its full-year ARR and revenue outlook.